

Anti-Allergic and Anti-Asthmatic Activity of Helioscopinin-A, a Polyphenol Compound, Isolated from *Euphorbia helioscopia*

PARK, KWAN HA², DONGSOO KOH³, SEUNGHO LEE⁴, ILLMIN JUNG⁵, KYUNG HYUN KIM⁶, CHUL-HOON LEE⁷, KYE-HOON KIM⁸, AND YOONGHO LIM^{1*}

¹Department of Applied Biology and Chemistry, Konkuk University, Seoul 143-701, Korea

²Department of Marine Biomedical Sciences, Kunsan National University, Chonbuk 573-702, Korea

³Department of Applied Chemistry, Dongduk Women's University, Seoul 136-716, Korea

⁴College of Pharmacy, Yeungnam University, Kyongpook 712-749, Korea

⁵Department of Crop Science, Konkuk University, Seoul 143-701, Korea

⁶Graduate School of Biotechnology, Korea University, Seoul 136-701, Korea

⁷Department of Medical Genetics and Institute of Biomedical Science, College of Medicine, Hanyang University, Seoul 133-791, Korea

⁸Department of Environmental Horticulture, The University of Seoul, Seoul 130-743, Korea

Received: November 1, 2000

Accepted: December 30, 2000

Abstract During the course of searching for anti-allergic substances from unexplored plant sources, an inhibitor of leukotriene D₄-induced tracheal contraction was isolated from *Euphorbia helioscopia*. This isolated polyphenol compound, known as helioscopinin-A, showed a certain inhibitory activity on capillary permeability in passive cutaneous anaphylaxis responses of rats and also on antigen-induced bronchial constriction in an experimental asthma model of guinea pigs. The compound at a high concentration weakly inhibited histamine release from isolated mast cells of rats. It is suggested that this compound is an anti-allergic and anti-asthmatic which exerts its activity through antagonism on leukotriene D₄-induced responses. A partial inhibition of allergic mediator release may also be involved.

Key words: *Euphorbia helioscopia*, helioscopinin-A, anti-asthma, anti-allergy

One-hundred-fifty aqueous, ethyl acetate, and methylene chloride extracts derived from 50 different plant species were selected on the basis of Korean traditional medicinal use as anti-allergic or anti-inflammatory agents. Of these, the ethyl acetate fraction of *Euphorbia helioscopia* was found to be active in inhibiting the leukotriene D₄ (LTD₄)-induced contraction of isolated guinea pig trachea in the primary screening.

E. helioscopia, widely distributed in Cheju Island of Korea as well as in Europe, is identified as a biannual

herbaceous plant. There are only a few reports on the plant pharmacology of *E. helioscopia*: molluscicidal activity [2]; skin irritating activity [24]; and efficacy for chronic bronchitis [11].

To identify the chemical nature of the active principle in *E. helioscopia*, an activity-guided fractionation of crude extract and its partitioned fractions was employed. Pharmacological characterization on the final constituent, helioscopinin-A [17], was performed, and it was found that the compound has dual inhibitory activities on the leukotriene D₄-induced response and on allergic mediator release from mast cells as well.

MATERIALS AND METHODS

General Analytical Equipments

Mass and NMR spectra were measured with the VG Micromass Autospec and Bruker ARX400 NMR spectrometer, respectively [16, 18, 21, 23].

Plant Material

The whole plants of *E. helioscopia* were collected in 1997 from the farmhouse in the College of Pharmacy, Yeungnam University, Kyongpook, Korea. The botanical identification was carried out by Seungho Lee and the voucher specimen was deposited in College of Pharmacy, Yeungnam University, Kyongpook, Korea.

Extraction and Isolation of the Active Compound

The compound showing LTD₄ antagonism was extracted, separated, and purified from the whole plants of *E. helioscopia*

*Corresponding author

Phone: 82-2-450-3760; Fax: 82-2-453-3761;

E-mail: yoongho@konkuk.ac.kr




Fig. 1. The procedure for the extraction, separation, and isolation of the active compound.

(dry wt 600 g), as shown in Fig. 1. The final active compound (about 10 mg) was obtained as a yellow crystal.

Identification of the Active Compound

The melting point ranged between 245°C and 247°C. The compound was freely soluble in acetone. Its molecular ion by FAB/MS was identified at m/z 953.7 (MH⁺). NMR spectra such as ¹H-NMR, ¹³C-NMR, Distortionless Enhancement of Polarization Transfer (DEPT) [8], Correlated Spectroscopy (COSY) [4], Homonuclear Hartmann Hahn Spectroscopy (HOHAHA) [3], Heteronuclear Multiple Quantum Coherence (HMQC) [5], and Heteronuclear Multiple Bond Correlation (HMBC) [6] were collected. Since 72 peaks were observed in the ¹³C-NMR spectrum, this observation did not agree with the result of MS. However, the ¹H-NMR spectrum, indicated that this compound is a mixture of 1:0.8. Therefore, the number of carbons in the compound could not be 72. Only half of these numbers could belong to one isomer. All peaks, except two peaks, were observed between 116.3 and 170.2 ppm and they were singlet peaks based on DEPT, where the compound could be assumed as being one of the polyphenols. This assumption was clarified by the ¹H-NMR spectrum which did not show a great number of peaks. Several compounds such as 12-




Fig. 2. Chemical structure of the isolated compound, helioscopinin-A.

deoxyphorbol-13-phenylacetate-20-acetate [24], hyperoside [1], *m*-hydroxyphenylglycine [19], 3,5-dihydroxyphenylglycine [19], helioscopinin-A [17], and helioscopinin-B [17] have been found in *E. helioscopia*. Among those, NMR and MS data of helioscopinin-A matched with those of our compound. Its structure is shown in Fig. 2.

Primary Screening of LTD₄ Antagonism

Male Hartley guinea pigs weighing 400–500 g were sacrificed by a sharp blow to the head and the trachea was removed. The trachea was opened by cutting along the ventral side, and two strips containing three cartilages each were sutured in parallel. The preparation was bathed in a jacketed 13 ml-organ bath filled with Krebs-Henseleit buffer (in mM: NaCl, 118; KCl, 4.7; CaCl₂, 2.5; MgSO₄, 1.6; NaHCO₃, 24.9; KH₂PO₄, 1.2; glucose, 11.0; pH 7.4 at 37°C). Contractile change was monitored by connecting the preparation to an isometric transducer and recorded on a chart-strip recorder. The bath was saturated by a continuous supply with 95% O₂ and 5% CO₂. Inhibitory effect of the test compounds on LTD₄ was examined by adding test compounds to the bath after the tracheal contraction with 5 nM LTD₄. Activity was expressed as the relaxant action induced by a test substance at fixed concentrations.

Pharmacology of Helioscopinin-A

Male Wistar rats (250–300 g) were treated with ovalbumin (1 mg, im) and 0.8 ml of pertussis vaccine (Difco, ip), and

IgE-containing serum was obtained 12 days later. Passive cutaneous anaphylaxis (PCA) test was performed with this serum as described by Katayama *et al.* [13]. For mast cell isolation, Wistar rats (male, about 250 g) were intraperitoneally injected with 20 ml of Tyrode solution and abdominal fluid was collected. Mast cells were purified by the Percoll density gradient method [9] and the effect of helioscopinin-A on histamine release from these cells was performed as described by Gomes *et al.* [12]. Inhibitory effect of helioscopinin-A on antigen-induced bronchial constriction was estimated in a passively sensitized asthma model of guinea pigs. Guinea pig anti-serum was prepared by injecting 1 mg of ovalbumin, emulsified in a 0.5 ml Freund's complete adjuvant, once a week for 4 weeks and taking serum 12 days later. Anti-ovalbumin serum (0.5 ml) was intravenously injected to fresh guinea pigs *via* the hind leg vein for production of asthma models [20]. Inhibitory effect of test substance on LTD₄-induced ileal contraction was measured, similarly to the tracheal preparations described above, except for a longitudinal ileal segment (approx. 1.5 cm, 2 g resting tension) instead of sutured tracheal sections.

RESULTS AND DISCUSSION

This study indicates that the polyphenol compound helioscopinin-A isolated from *E. helioscopia* possesses an anti-allergic and anti-asthmatic activity. This activity is explained by both the blockade of LTD₄-induced pharmacological action and a moderate inhibition of allergic mediator release.

Employing our standard assay system with isolated guinea pig trachea to discover inhibitors on LTD₄-induced functional responses, it was possible to isolate helioscopinin-A in a pure form after activity-guided fractionation. The inhibition rate in the overall steps was 43–65% at

Table 1. Primary screening with the extracts of *E. helioscopia* on relaxant effects of LTD₄-induced contraction in isolated guinea pig trachea.

Separation steps (Refer to Fig. 1)	Extract code	Concentration (µg/ml)	Relaxant activity (%)
Positive reference	FPL-55712 ⁺	100	57.7±8.1
I	EH-water	1,000	48.8±7.8(*)
	EH-CH ₂ Cl ₂		11.2±6.3
II	EH-EtOAc	1,000	52.3±9.4(*)
	EH-H ₂ O		10.3±6.2
III	Fr-1	500	0.0±0.6
	Fr-2		0.8±2.4
	Fr-3		43.3±8.1(*)
	Fr-4		15.5±4.5
	Fr-5		4.3±2.6
IV	Fr-3-1	500	0.3±2.2
	Fr-3-2		0.0±0.0
	Fr-3-3		2.6±2.4
	Fr-3-4		61.2±4.8
	Fr-3-5		25.0±6.7
	Fr-3-6		13.0±3.6
	Fr-3-7		10.2±0.4
	Fr-3-8		4.8±0.2

Data as mean±SEM of 3–5 determinations. (*) Fractions used for further separation steps. Fr-3-4: helioscopinin-A. + is known to be the first leukotriene antagonist, which is effective in blocking LTD₄-induced guinea pig tracheal smooth muscle contraction [14].

concentrations of 500–1,000 µg/ml in the fractions which possessed the best possible activity (Table 1). A weak inhibition was also observed in some additional fractions such as Fr-4, Fr-3-5, Fr-3-6, and Fr-3-7. Since we did not pursue any further on these moderately active additional fractions, it was not possible to judge whether this extra activity was caused by unidentified principle(s) or to

Table 2. Effects of helioscopinin-A on allergic responses and LTD₄-induced functions.

Tests	Parameters	Helioscopinin-A	n	Effect (% inhibition)
Rat PCA response	Dye diameter	45 mg/kg (i.v.)	5	79.3±7.3
	Dye content			67.5±7.1
Rat mast cell HA release	Compound 48/80-induced A 23187-induced	1 mg/ml	7	13.4±2.2 21.3±5.0
Asthmatic bronchial constriction	Maximal inflation pressure increase	30 mg/kg (i.v.)	5	38.7±2.4
LTD ₄ -induced tracheal contraction		0.1 mg/ml		12.5±0.9
		0.5 mg/ml		54.3±7.4
		1 mg/ml		68.8±5.9
LTD ₄ -induced ileal contraction		0.1 mg/ml		20.4±7.5
		1 mg/ml		32.2±6.6

Data as mean±SEM of n determinations. PCA: passive cutaneous anaphylaxis; HA: histamine.

helioscopinin-A being incompletely resolved during the separation procedures.

It has been proposed that LTD₄ is one of the most important mediators in allergic asthma [25]. Thus, it may be reasonable to suggest that an agent which possesses LTD₄ antagonism can be a candidate for an asthma therapeutant. However, we cannot presently distinguish whether helioscopinin-A inhibits at the receptor level or at steps ensuing LTD₄-LTD₄ receptor interaction, e.g. the contractile process of the smooth muscle. The test compound of helioscopinin-A also inhibited PCA responses in both dye exudation and tissue dye contents (Table 2). As PCA responses in experimental animals are mediated by several mediators such as histamine, leukotrienes, prostaglandins, serotonin (5-HT), or platelet-activating factor [15], the observed inhibitory effects of helioscopinin-A seem to be contributed both by direct LTD₄ antagonism and release suppression of these mediators.

Most anti-asthmatic agents have limitations in their efficacy, probably due to multiple pathophysiological mechanisms involved in its etiology. As promising anti-asthmatic agents, compounds which have dual action mechanisms may be desirable, since they might be more effective than those with a simple pharmacological mechanism.

Helioscopinin-A exhibited a relatively weaker inhibitory action on the LTD₄ response in the guinea pig ileum than in the trachea. There is a slight difference in LTD₄ receptors between those present in the bronchial smooth muscle and the ileum of guinea pigs [10]. Even though not strictly selective, a compound with organ-specific pharmacologic action is desirable.

Overall, our results suggest that helioscopinin-A may be useful in the therapy of allergic diseases, especially allergic asthma. Since its activity is not potent enough for clinical use, further chemical modification may be necessary.

Acknowledgment

This work was supported by a grant (HMP-97-D-4-0020) from the Korea Ministry of Health and Welfare.

REFERENCES

1. Abdel-Salam, N., M. El-Sayed, and S. Khafagy. 1975. Spectrophotometric estimation of individual flavone glycosides in three *Euphorbia* species. *Pharmazie* **30**: 402-403.
2. Al-Zanbagi, N., A. Banaja, and J. Barrett. 2000. Molluscicidal activity of some Saudi Arabian euphorbiales against the snail *Biomphalaria pfeifferi*. *J. Ethnopharmacol.* **70**: 119-125.
3. Bax, A. and D. Davis. 1985. MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy. *J. Magn. Reson.* **65**: 355-360.
4. Bax, A. and R. Freeman. 1981. A simple method for suppressing dispersion-mode contributions in nmr spectra: The "pseudo echo". *J. Magn. Reson.* **43**: 333-338.
5. Bax, A., R. Griffey, and B. Hawkins. 1983. Correlation of proton and nitrogen-15 chemical shifts by multiple quantum nmr. *J. Magn. Reson.* **55**: 301-315.
6. Bax, A. and M. Summers. 1986. ¹H and ¹³C assignments from sensitivity-enhanced detection of heteronuclear multiple-bond connectivity by 2D multiple quantum nmr. *J. Am. Chem. Soc.* **108**: 2093-2094.
7. Breitmaier, E. and W. Voelter. 1989. In *Carbon-13 nmr Spectroscopy*. pp. 381-384. VCH, New York, U.S.A.
8. Dodrell, D., D. Pegg, and M. Bendall. 1982. Distortionless enhancement of nmr signals by polarization transfer. *J. Magn. Reson.* **48**: 323-327.
9. Enerback, L. and I. Svensson. 1980. Isolation of rat peritoneal mast cells by centrifugation on density gradients of Percoll. *J. Immunol. Methods* **39**: 135-145.
10. Gardiner, P., T. Abram, S. Tudhope, N. Cuthbert, P. Norman, and C. Brink. 1994. Leukotriene receptors and their selective antagonists. pp. 49-61. In: *Advances in Prostaglandin, Thromboxane, and Leukotriene Research*. vol. **22**. Raven Press, New York, U.S.A.
11. Ghen, Y., Z. Tang, F. Jiang, X. Zhang, and A. Lao. 1979. Studies on the active principles of *Ze-Qi* (*Euphorbia helioscopia* L.), a drug used for chronic bronchitis. *Yao Hseuh Pao* **14**: 91-95.
12. Gomes, J., L. Di Stasi, F. Sgarbosa, and L. Barata. 1994. Pharmacological evaluation of the inhibitory effect of extracts from *Anchietia salutaris* on the histamine release induced in the rat and the guinea pig. *Int. Arch. Allergy Immunol.* **103**: 188-193.
13. Katayama, S., H. Shionoya, and S. Ohtake. 1978. A new method for extraction of extravasated dye in the skin and influence of fasting stress on passive cutaneous anaphylaxis in guinea pigs and rats. *Microbiol. Immunol.* **22**: 89-101.
14. Kingsbury, W., R. Daines, and J. Gleason. 1990. Leukotriene receptors, pp. 763-804. In C. Hansch (ed.), *Comprehensive Medicinal Chemistry*, vol. **3**. Pergamon Press, New York, U.S.A.
15. Koda, A., T. Miura, N. Inagaki, O. Sakamoto, A. Arimura, H. Nagai, and H. Mori. 1990. A method for evaluating anti-allergic drugs by simultaneously induced passive cutaneous anaphylaxis and mediator cutaneous reactions. *Int. Arch. Allergy Appl. Immunol.* **92**: 209-216.
16. Lee, C.-H., H. Kyung, and Y. Lim. 2000. Comparison of the solution structure of vancomycin with its x-ray crystallographic structure. *J. Microbiol. Biotechnol.* **10**: 733-736.
17. Lee, S., T. Tanaka, G. Nonaka, and I. Nishioka. 1990. Tannins and related compounds. XCV. Isolation and characterization of helioscopinins and helioscopins, four new hydrolysable tannins from *Euphorbia helioscopia* L. *Chem. Pharm. Bull.* **38**: 1518-1523.
18. Lim, S. and W. Park. 1999. Isolation of sphinin, an inhibitor of sphingomyelinase, from *Streptomyces* sp. F50970. *J. Microbiol. Biotechnol.* **9**: 655-660.

19. Muller, P. and H. Schutte. 1968. m-Hydroxyphenylglycin and 3,5-dihydroxyphenylglycin, 2 new amino acids from the latex of *Euphorbia helioscopia* L. *Z. Naturforsch. B.* **23**: 659–663.
20. Nagai, H., T. Sakurai, T. Iwama, S. Yamaguchi, K. Kitagaki, N. Inagaki, and A. Koda. 1993. Effects of MKS-492 on antigen-induced bronchoconstriction and allergic reaction in guinea pigs and rats. *Jpn. J. Pharmacol.* **63**: 405–413.
21. Park, H., Y. Lim, Y. Kim, and K. Kyung. 1999. 10-Hydroxyoctadecanoic acid produced by *Lactococcus lactis* subsp. *Lactis* as a part of flocculent aggregate. *J. Microbiol. Biotechnol.* **9**: 39–43.
22. Roesch, A., W. Schaumann, and O. Wilhelms. 1989. Antiallergic activity of picumast dihydrochloride in several animal species. *Arzneim.-Forsch./Drug Res.* **39**: 1310–1316.
23. Ryu, J., S. Lee, S. Lee, D. Kim, S. Cho, S. Park, D. Bae, K. Park, and H. Yun. 2000. Screening and identification of an antifungal *Pseudomonas* sp. that suppresses balloon flower root rot caused by *Rhizoctonia solani*. *J. Microbiol. Biotechnol.* **10**: 435–440.
24. Schmidt, R. and F. Evans. 1980. Skin irritants of the sun spurge (*Euphorbia helioscopia* L.). *Contact Dermatitis* **6**: 204–210.
25. Weichman, B., M. Wasserman, D. Holden, R. Osborn, D. Woodward, T. Ku, and J. Gleason. 1983. Antagonism of the pulmonary effects of the peptidoleukotrienes by a leukotriene D₄ analog. *J. Pharmacol. Exp. Ther.* **227**: 700–705.